Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Market Closed 08-07 16:00:00 EDT

30.20

+0.66

+2.23%

盘后30.20

+0.000.00%

19:39 EDT

High30.77	Low29.25	Vol30.35K
Open29.92	D1 Closing29.54	Amplitude5.15%
Mkt Cap29.53M	Tradable Cap24.85M	Total Shares977.97K
T/O912.89K	T/O Rate3.69%	Tradable Shares823.00K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":30.2,"timestamp":1786132800000,"preClose":29.54,"halted":0,"volume":30354,"hourTrading":{"tag":"盘后","latestPrice":30.2,"preClose":30.2,"latestTime":"19:39 EDT","volume":148,"amount":4253.91,"timestamp":1786145940771,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.022342586323628982,"floatShares":823000,"shares":977965,"eps":-182.15,"marketStatus":"Market Closed","change":0.66,"latestTime":"08-07 16:00:00 EDT","open":29.92,"high":30.77,"low":29.25,"amount":912889.234686,"amplitude":0.051456,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-182.15,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":29.54,"preHourTrading":{"tag":"盘前","latestPrice":29.2,"preClose":29.54,"latestTime":"09:28 EDT","volume":131,"amount":3851.209788,"timestamp":1786109298980,"change":-0.34,"changeRate":-0.01151,"amplitude":0.068382},"postHourTrading":{"tag":"盘后","latestPrice":30.2,"preClose":30.2,"latestTime":"19:39 EDT","volume":148,"amount":4253.91,"timestamp":1786145940771,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8204279950256658,"impliedVol":2.224,"impliedVolPercentile":0.6471},"requestUrl":"/m/hq/s/QNCX/wiki","defaultTab":"wiki","newsList":[{"id":"2657108216","title":"Quince Therapeutics, Inc. Expected to Post a Loss of $17.88 a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657108216","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657108216?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:01","pubTimestamp":1786100494,"startTime":"0","endTime":"0","summary":"Quince Therapeutics, Inc. <QNCX.OQ> expected to post a loss of $17.88 a share - Earnings PreviewQuince Therapeutics, Inc.QNCX.OQQNCX.Ois expected to  show no change in quarterly revenue when it report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440XH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656916773","title":"Quince Therapeutics - Brigette Roberts Conditionally Appointed as Chief Executive Officer - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656916773","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656916773?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:52","pubTimestamp":1785531128,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2NT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391678","title":"Quince Therapeutics Names Brigette Roberts CEO in Management Reshuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391678","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391678?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:51","pubTimestamp":1785531091,"startTime":"0","endTime":"0","summary":"Quince Therapeutics names Brigette Roberts CEO in management reshuffleQuince Therapeutics disclosed conditional resignations by CEO and Chief Medical Officer Dirk Thye, effective two business days aft","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL1LRSVx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","RCKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391692","title":"Quince Therapeutics Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391692","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391692?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:49","pubTimestamp":1785530953,"startTime":"0","endTime":"0","summary":"Quince Therapeutics announces special shareholder meetingQuince Therapeutics will hold a virtual special shareholder meeting in September 2026.Votes will be sought to allow conversion of Series C Non-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL3LJWjB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656688391","title":"Quince Therapeutics - Offers 15,470,099 Shares of Common Stock for Resale - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656688391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656688391?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:46","pubTimestamp":1785530791,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2AM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655389160","title":"Analysts Offer Insights on Healthcare Companies: Quince Therapeutics (QNCX) and Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655389160","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655389160?lang=en_us&edition=fundamental","pubTime":"2026-07-31 04:50","pubTimestamp":1785444632,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Quince Therapeutics (QNCX) and Opus Genetics (IRD) w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quince-therapeutics-qncx-and-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-quince-therapeutics-qncx-and-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HCSG","QNCX","XLV","BK4588","BK4139","XBI","BK4137","BK4581","IRD","LU0029874061.USD","LABU","BK4585","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655602628","title":"Quince Therapeutics : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $82","url":"https://stock-news.laohu8.com/highlight/detail?id=2655602628","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655602628?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:23","pubTimestamp":1785327781,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V1V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553741","title":"Quince Therapeutics Appoints Paul Yu to Chair New Pulmonary Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553741","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553741?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:04","pubTimestamp":1782821048,"startTime":"0","endTime":"0","summary":"Quince Therapeutics appoints Paul Yu to chair new pulmonary scientific advisory boardQuince Therapeutics formed a Scientific Advisory Board to support development of LAM-001, an inhaled rapamycin form","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL7GjtHy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4588","IE00BKPKM429.USD","IE00B64PRP62.GBP","NDAQ","SG9999014021.USD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2W23.USD","BK4139","IE00BN0W2T93.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","BK4585","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553942","title":"Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553942","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553942?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:00","pubTimestamp":1782820808,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA11ZGTF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646962394","title":"Take-Two, Quince, Tonix, CoreWeave, Affirm Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2646962394","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646962394?lang=en_us&edition=fundamental","pubTime":"2026-06-27 17:01","pubTimestamp":1782550888,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($TTWO) ), ( ($QNCX) ), ( ($TNXP) ), ( ($CRWV) ) and ( ($AFRM) ). Here is a breakdown of their recent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/take-two-quince-tonix-coreweave-affirm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/take-two-quince-tonix-coreweave-affirm-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4106","BK4548","CRWU","LU2360107168.USD","TTWO","BK4524","BK4227","AFRU","LU1861215975.USD","TNXP","BK4139","CRWV","LU1861220207.SGD","BK4535","CORD","LU1280957306.USD","LU1861220033.SGD","CRWG","BK4583","LU2290526834.HKD","BK4588","LU0082616367.USD","LU0640476718.USD","CWII","CWVX","AFRM","QNCX","LU1323610961.USD","LU1861217088.USD","BK4085","LU0719512351.SGD","LU0081259029.USD","LU1861558580.USD","BK4585","LU1861559042.SGD","LU0061475181.USD","BK4116","BK4554","LU2360107671.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646171360","title":"Quince Therapeutics Amends 8-K to Correct Reverse Stock Split Description","url":"https://stock-news.laohu8.com/highlight/detail?id=2646171360","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646171360?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:31","pubTimestamp":1782505915,"startTime":"0","endTime":"0","summary":"Quince Therapeutics amends 8-K to correct reverse stock split descriptionQuince Therapeutics filed an amended 8-K to correct an error in its disclosure of a planned reverse stock split.The amendment restated the terms as a 1-for-20 reverse split, effective 11:59 p.m. ET June 29, 2026.Split-adjusted trading is set to start at the June 30, 2026 market open under ticker QNCX with new CUSIP 22053A305.Shares outstanding are expected to fall to about 977,963 from 19,559,257, with fractional shares rounded up.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL3plnP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642321402","title":"Quince Therapeutics files Form 3 for director, Chief Corporate Affairs Officer Brigette Roberts","url":"https://stock-news.laohu8.com/highlight/detail?id=2642321402","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642321402?lang=en_us&edition=fundamental","pubTime":"2026-06-12 05:28","pubTimestamp":1781213332,"startTime":"0","endTime":"0","summary":"Quince Therapeutics filed an initial Form 3 for Brigette Roberts, director and chief corporate affairs officer, covering her insider holdings as of May 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL7Tmszv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642323282","title":"Quince Therapeutics shareholders approved reverse stock split authorization range of 1-for-10 to 1-for-100","url":"https://stock-news.laohu8.com/highlight/detail?id=2642323282","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642323282?lang=en_us&edition=fundamental","pubTime":"2026-06-12 05:07","pubTimestamp":1781212044,"startTime":"0","endTime":"0","summary":"Quince Therapeutics held its annual shareholder meeting on June 11, 2026.Shareholders backed an amendment to authorize a reverse stock split, allowing a 1-for-10 to 1-for-100 ratio at the board’s discretion.The reverse split was authorized, not executed; timing and final ratio remain subject to a separate board decision.Shareholders also authorized an adjournment if needed to continue soliciting proxies for the meeting’s proposals.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsibl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL51ctLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637390357","title":"Quince Therapeutics regains Nasdaq listing compliance after equity rises to $15.67 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637390357","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637390357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:07","pubTimestamp":1779397654,"startTime":"0","endTime":"0","summary":"Quince Therapeutics regained compliance with Nasdaq Global Market continued listing standards, closing a prior deficiency tied to the minimum market value of listed securities requirement.Nasdaq had issued a notice on March 17, 2026, citing failure to maintain a $50 million minimum market value of listed securities over 30 consecutive business days under Listing Rule 5450.A May 20, 2026 letter from Nasdaq said the company now meets Listing Rule 5450 based on stockholders’ equity of $15.67 million reported in its quarterly filing for the period ended March 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gather","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDLbckKxB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636792820","title":"Quince Therapeutics announces LAM-001 data","url":"https://stock-news.laohu8.com/highlight/detail?id=2636792820","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636792820?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:41","pubTimestamp":1779111664,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin, in patients with pulmonary arterial hyp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-lam-001-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-announces-lam-001-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","QNCX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636498079","title":"Quince Therapeutics acquires Orphai Therapeutics, terms undisclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2636498079","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636498079?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:35","pubTimestamp":1779111306,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) announced it has acquired Orphai Therapeutics. The acquisition brings Orphai’s program LAM-001, an inhaled formulation o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-acquires-orphai-therapeutics-terms-undisclosed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-acquires-orphai-therapeutics-terms-undisclosed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX","BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079919","title":"Quince Therapeutics prices private placement raising up to $187 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079919","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079919?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:34","pubTimestamp":1779111273,"startTime":"0","endTime":"0","summary":"Quince Therapeutics entered a private placement to raise up to USD 187 million in gross proceeds tied to an unregistered sale of Series C non-voting convertible preferred stock.The deal includes USD 115 million of upfront proceeds, with up to about USD 72 million more available from warrant exercises.Balyasny Asset Management led the financing, with participation from several other healthcare-focused investors.Proceeds, together with cash at closing, are expected to fund operations through end-2028, supporting LAM-001 development with Phase 2 BOS data targeted for Q1 2027 and Phase 2b PH-ILD data targeted for Q1 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9fVMzY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079673","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079673","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079673?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:33","pubTimestamp":1779111221,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:33 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nAQN2LZF7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636079392","title":"Quince Therapeutics acquires Orphai Therapeutics, adds inhaled rapamycin program LAM-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2636079392","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636079392?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110829,"startTime":"0","endTime":"0","summary":"Quince Therapeutics has acquired clinical-stage Orphai Therapeutics, adding lead asset LAM-001, an inhaled rapamycin formulation being developed for pulmonary diseases including PH-ILD and bronchiolitis obliterans syndrome.The stock-for-stock deal exchanges Orphai equity for 3,258,517 Quince common shares, 67,101 shares of Series C non-voting convertible preferred stock, options for 26,332,798 common shares, and replacement warrants that could generate about $10.9 million if exercised.A concurrent private placement is set to raise up to $187 million in gross proceeds, including $115 million upfront, with up to about $72 million tied to warrant exercise; closing is expected May 21, 2026.On a fully diluted basis assuming full conversion of the Series C preferred, pre-deal Quince holders are expected to own about 6.9%, legacy Orphai holders about 31.9%, and private placement investors about 61.2%.Cash from the financing and existing balances are expected to fund operations through end-202","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL1hYrfV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","NDAQ","SG9999014039.USD","BK4139","QNCX","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","BK4588","BK4585","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636307936","title":"Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2636307936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636307936?lang=en_us&edition=fundamental","pubTime":"2026-05-18 21:27","pubTimestamp":1779110823,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nFWN41V0R1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QNCX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":0.2912},{"period":"1month","weight":0.7507},{"period":"3month","weight":0.1797},{"period":"6month","weight":0.0855},{"period":"1year","weight":-0.9096},{"period":"ytd","weight":-0.9549}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.091321},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.101646},{"month":3,"riseRate":0.428571,"avgChangeRate":0.087035},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.03031},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.092353},{"month":6,"riseRate":0.625,"avgChangeRate":0.135399},{"month":7,"riseRate":0.375,"avgChangeRate":-0.03183},{"month":8,"riseRate":0.5,"avgChangeRate":0.065229},{"month":9,"riseRate":0.571429,"avgChangeRate":0.013938},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.049658},{"month":11,"riseRate":0.571429,"avgChangeRate":0.199459},{"month":12,"riseRate":0.285714,"avgChangeRate":0.079276}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction